{"ModuleTitle": "Company Description", "CompanyName": "Clovis Oncology, Inc.", "Symbol": "CLVS", "Address": "5500 FLATIRON PARKWAY SUITE 100, BOULDER, Colorado, 80301, United States of America", "Phone": "(303) 625-5000", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a biopharmaceutical company focused on acquiring, developing and\r\ncommercializing innovative anti-cancer agents in the United States, Europe and\r\nadditional international markets. We target our development programs for the\r\ntreatment of specific subsets of cancer populations, and simultaneously develop,\r\nwith partners, for those indications that require them, diagnostic tools\r\nintended to direct a compound in development to the population that is most\r\nlikely to benefit from its use.\r\n\r\n \r\n\r\nOur marketed product Rubraca\u00ae (rucaparib), an oral small molecule inhibitor of\r\npoly ADP-ribose polymerase (\"PARP\"), is marketed in the United States for two\r\nindications specific to recurrent epithelial ovarian, fallopian tube or primary\r\nperitoneal cancer.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f26%2f0001558370-20-001500.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Daniel W. Muehl", "title": "CFO, Principal Accounting Officer & Executive VP"}, {"name": "Lindsey Rolfe", "title": "Chief Medical Officer & Executive VP-Clinical"}, {"name": "Patrick J. Mahaffy", "title": "President, Chief Executive Officer & Director"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}